Results per Page:
For many blood cancer patients, CAR T-cell therapy is game-changing
In this episode of From Bench to Bedside and Beyond, Dr. Mazyar Shadman explains why CAR T-cell therapy should be considered for patients who relapse
Grateful for her husband’s life-saving care, she vowed to get a job at Fred Hutch
In this episode of From Bench to Bedside and Beyond, Tiffany Bucklin talks about her husband’s treatment for leukemia
Gratitude for life-saving care at Fred Hutch leads to endowed chair
Dr. Madhav Dhodapkar is the recipient of the Milton B. Rubin Family Endowed Chair
Switching sides: How MLL-rearranged leukemias leverage oncoproteins to evade treatment
From the Henikoff Lab, Basic Sciences Division
When more isn’t more for AML patients undergoing hematopoietic stem cell transplant
From the Walter and Storb Labs, Translational Sciences and Therapeutics Division
Weighing the benefits of hematopoietic stem cell transplantation for older and medically infirm patients with acute myeloid leukemia
From the Sorror Group, Clinical Research Division
Leader in apheresis and cellular therapy, Dr. Michael Linenberger, retires
As professor emeritus, this respected mentor will continue to contribute to the UW fellowship program
Eight Fred Hutch teams win Evergreen Fund awards
Research projects with commercial partnership potential receive grants of up to $200K
How does leukemia escape from immunotherapy?
Single-cell sequencing tech enables deep dive into mysterious results, sets stage for future improvements
Thwarting relapse in patients with acute myeloid leukemia
From the Hill Lab, Clinical Research Division
Send in the CARs: mesothelin-targeted CAR T cells against AML
From the Meshinchi Lab, Clinical Research Division, and Cancer Consortium colleagues
Two Fred Hutch postdocs named 2021 Damon Runyon Fellows
Awards to Drs. Edie Crosse and Ching-Ho Chang fund ‘creative, high-risk projects’ in cancer research
Taking aim: Mesothelin as a novel target for pediatric AML therapy
From the Meshinchi Lab, Clinical Research Division, and Cancer Consortium colleagues
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
From the Walter Lab, Clinical Research Division